ATE71146T1 - Retroviraler vektor. - Google Patents

Retroviraler vektor.

Info

Publication number
ATE71146T1
ATE71146T1 AT85401914T AT85401914T ATE71146T1 AT E71146 T1 ATE71146 T1 AT E71146T1 AT 85401914 T AT85401914 T AT 85401914T AT 85401914 T AT85401914 T AT 85401914T AT E71146 T1 ATE71146 T1 AT E71146T1
Authority
AT
Austria
Prior art keywords
cells
retroviral vector
promoter
gene
ltr
Prior art date
Application number
AT85401914T
Other languages
English (en)
Inventor
Francois Jacob
Jean-Francois Nicolas
John Rubenstein
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE71146T1 publication Critical patent/ATE71146T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
AT85401914T 1984-10-01 1985-10-01 Retroviraler vektor. ATE71146T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848424757A GB8424757D0 (en) 1984-10-01 1984-10-01 Retroviral vector
EP85401914A EP0178220B1 (de) 1984-10-01 1985-10-01 Retroviraler Vektor

Publications (1)

Publication Number Publication Date
ATE71146T1 true ATE71146T1 (de) 1992-01-15

Family

ID=10567514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85401914T ATE71146T1 (de) 1984-10-01 1985-10-01 Retroviraler vektor.

Country Status (4)

Country Link
EP (1) EP0178220B1 (de)
AT (1) ATE71146T1 (de)
DE (1) DE3585072D1 (de)
GB (1) GB8424757D0 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690297B2 (ja) * 1985-08-05 1997-12-10 東レ株式会社 有用たん白質の産生方法
JPH0630590B2 (ja) * 1985-08-30 1994-04-27 株式会社ヤクルト本社 複合プラスミドベクタ−
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
DE3636287A1 (de) * 1986-10-24 1988-04-28 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von stoffwechselprodukten in eukaryontenzellen
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
AU1782288A (en) * 1987-04-23 1988-12-02 State of Oregon Acting by and through the State Board of Higher Education on behalf ofOregon Health Sciences University Process for the amplifying expression and transmission of cloned genes in eukaryotic cells
GB8720855D0 (en) * 1987-09-04 1987-10-14 Oxford University Of Chancello Probe
ATE117375T1 (de) * 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
PT88556B (pt) * 1987-09-28 1992-11-30 Smithkline Biolog Processo de integracao genomica estavel e de expressao de uma sequencia de cadificacao estranha, em leveduras
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
FR2629469B1 (fr) * 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
JPH04504950A (ja) * 1988-11-23 1992-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 位置特異的挿入ベクターおよびこれを用いた方法
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
JP3203599B2 (ja) * 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
JPH07501942A (ja) * 1991-11-29 1995-03-02 カイロン　コーポレイション 抗ガン免疫療法用ベクター構成体
GB2269175A (en) * 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2704236B1 (fr) * 1993-04-21 1995-06-23 Pasteur Institut Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique.
AU688321B2 (en) * 1993-04-21 1998-03-12 Institut Pasteur Biocompatible implant for the expression and secretion in vivo of a therapeutic compound
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
EP1049767B1 (de) 1998-01-08 2005-08-17 Aventis Pharmaceuticals Inc. Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
US6743631B1 (en) 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
WO2002053761A2 (en) 2000-12-28 2002-07-11 Wyeth Recombinant protective protein from $i(streptococcus pneumoniae)
US7582425B2 (en) 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin
US7108975B2 (en) 2001-09-21 2006-09-19 Regents Of The University Of Michigan Atlastin
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1506286B1 (de) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralisierung eines menschlichen anti-igfr-antikörpers
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
SG173414A1 (en) 2006-07-28 2011-08-29 Sanofi Aventis Fr Composition and method for treatment of tumors
AU2007319605B2 (en) 2006-10-19 2011-02-17 Csl Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
PL2829551T3 (pl) 2006-10-19 2018-04-30 Csl Limited Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9063123B2 (en) 2011-03-29 2015-06-23 Dynavax Technologies Corporation Transgenic mice expressing human toll-like receptor 8
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7813706B2 (ja) 2020-01-03 2026-02-13 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるｔｎａｐ
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US20240352456A1 (en) 2021-05-13 2024-10-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating sickle cell diseases
WO2023064255A2 (en) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
US20250206796A1 (en) 2022-04-13 2025-06-26 The Regents Of The University Of California Use of viral il-6 in cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192658A4 (de) * 1984-07-30 1987-07-13 Salk Inst For Biological Studi Retrovirale gentransfervektoren.

Also Published As

Publication number Publication date
EP0178220B1 (de) 1992-01-02
GB8424757D0 (en) 1984-11-07
EP0178220A2 (de) 1986-04-16
DE3585072D1 (de) 1992-02-13
EP0178220A3 (en) 1987-08-26

Similar Documents

Publication Publication Date Title
ATE71146T1 (de) Retroviraler vektor.
GB9510272D0 (en) Retroviral vectors
Knight et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing
WO1993024641A3 (en) Adeno-associated virus with inverted terminal repeat sequences as promoter
DE69829471D1 (de) Auf lentivirus basierende gentransfer-vektoren
DE3586520D1 (de) Herpes simplex-virus als vektor.
WO1996037623B1 (en) Retroviral vectors
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
Vile et al. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter
GB2331522A (en) Lentiviral vectors
ATE223493T1 (de) Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
WO2001036620A3 (en) Vectors and transgenies with regulatory elements for gene delivery to the liver
WO1992005266A3 (en) Packaging cells
AU2768992A (en) Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
GB8718779D0 (en) Dna sequence & expression vector
Boulter et al. A universal retroviral vector for efficient constitutive expression of exogenous genes
EP1359223A3 (de) WtAAV-freie Herstellung von rekombinanten AAV
Baum et al. Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection
DK0801575T3 (da) Retrovirale vektorer til ekspression i embryoniske celler
GB2322131A (en) Improved retroviral vectors for gene therapy
ATE277191T1 (de) Retrovirale vektoren für die transduktion des beta-globingens, sowie derivaten der beta-ort kontrollierten region des beta-orts
DE3877233D1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
Moore et al. Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector
Vile The retroviral life cycle and the molecular construction of retrovirus vectors
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties